GBIM undiscovered and Cheapest Hepatitis Play you can get on the Stockmarket . Important Phase 2 Results of their Hep B Drug (partnered with Gilead) in 2Q if Positive then you can expect a share price explsoion because of its extreme low float .
Globeimmune (GBIM)
Market Cap: $42 Million
Cash $17 Million
Price $7.30
Shares Out: 5.7 Million
GBIM is the Cheapest Hepatitis Play you can get on the Stockmarket with a laughable Market Cap of $42 Million and $17 Million in Cash . GBIM is partnered with World Class Biotechs Gilead and Celgene and Celgene is the largest Shareholder of this undiscovered Goldmine . There are only 5.7 Million Shares Outstanding means if Phase 2 results are positive then this one will explode like a Nuclear bomb .GL
GS-US-330-0101, or the 0101 trial, is a randomized Phase 2 clinical trial, initiated in 2013, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial is a multicenter, multinational trial that enrolled 175 patients in a randomized, open-label design comparing three different doses of GS-4774, administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial is decline in serum HBV surface antigen, or HBsAg. The 0101 trial is fully-enrolled, and 48-week results are expected to be available in the first half of 2015. These results may be submitted to an upcoming scientific conference.
We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic progression of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through March 31, 2014, we have received over $60 million from these collaborations.
